In a previous study, the i-body CXCR4 antagonist, AD-114, reduced experimental lung fibrosis and decreased IPF lung fibroblast invasion in-vitro [8], which supports the targeting of CXCR4 as a therapeutic option in IPF. Here, CXCR4 is linked to idiopathic pulmonary fibrosis.